- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06689930
Mise en œuvre communautaire du STAC
Promotion et prévention de la santé à base communautaire modifiant le maintien en bonne santé après (autour) de l'accouchement avec hypertension pendant la grossesse jusqu'au post-partum
This study is being done to adapt the Staying Healthy After Childbirth (STAC) intervention for implementation among Black Women and Birthing Persons (WBP).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Hypertensive disorders of pregnancy (HDP) are windows into chronic disease risk. The immediate postpartum (PP) period (6 weeks) is the highest risk and most important period for prevention of serious adverse outcomes with long term consequences. This project focuses on a multicomponent evidence-based intervention, Staying Healthy After Childbirth (STAC) that has been tested in a Midwest academic hospital. The intervention has been shown to be effective at addressing factors associated with health promotion priorities in populations with high levels of health disparities and inequities by increasing access to hypertension (HTN) care in the critical PP window by providing patients a home blood pressure monitor and access to a dedicated healthcare team that provides remote BP surveillance and antihypertensive medication titration. To optimize STAC to prevent and reduce racial disparities in immediate PP morbidity and mortality, deeper engagement with community stakeholders is critical.
This is a qualitative investigation designed as pre-implementation of the Adapted Staying Healthy After Childbirth (A-STAC) intervention.
STAC-Community Advisory Board (CAB) members and Lived Experience Group members will provide qualitative data through semi-structured interviews regarding implementation factors of STAC, including priorities for adaptation, barriers and facilitators to implementation, and usability. Rapid qualitative analysis will be used to glean themes from the qualitative data. A second round of semi-structured focus groups using the nominal decision-making process will be conducted to address the revisions to implementation strategies and determine priorities for A-STAC. Next, abbreviated study cycles to test implementation (Plan-Do-Study-Act or PDSA cycles) will take place, with Community Based Organization (CBO) partners and participating Black pregnant persons. After each PDSA cycle, interviews and surveys with patients and staff will be conducted. Rapid qualitative analysis will again be used to gain information about the usability of A-STAC from the focus group; this information will then be used to refine the A-STAC intervention. This process will be repeated for a second PDSA cycle (up to three PDSA cycles total), after which the A-STAC intervention will be finalized for implementation (registered to a separate ClinicalTrials.gov record).
Step 1: Conduct interviews with STAC-CAB members (8-12 members) and Lived Experience Group members (8-12 members) to evaluate implementation factors and priorities for adaptation of STAC.
Use rapid qualitative analysis process to glean implementation strategies.
Step 2: Conduct small focus groups (3-4 participants per group) with STAC-CAB members (8-12 members) and Lived Experience Group members separately using nominal group decision decision making process.
Address revisions to implementation strategies and priorities for A-STAC.
Step 3: Conduct PDSA cycles and follow-up interviews and surveys for patients (3-5 participants per cycle, 10 total) and CBO staff (at least 2 staff).
Step 4: Incorporate usability data from cycle 1 to refine A-STAC.
Repeat steps 3-4 for additional PDSA cycles (up to 3).
Step 5: Finalize A-STAC Intervention.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53792
- University of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria (Interviews and Focus Groups):
- Belong to the STAC-CAB or Lived Experience Group
- Aged 18 or older
Inclusion Criteria (CBO Staff):
- Staff of CBO participating in PDSA cycle
- Aged 18 years or older
Inclusion Criteria (PDSA-Cycles):
- Pregnant persons greater than or equal to 24 weeks gestation and prior to delivery or postpartum
- Self-Identify as African American or Black
- Aged 18 years or older
- Capable of providing informed consent in English
- Can follow M•care System use instructions in English
- Have ownership of a functioning and reliable smartphone to upload and use the M•other App
- Interested in preventing or managing blood pressure during pregnancy
Exclusion Criteria (PDSA-Cycles):
- Persistent second or third trimester bleeding at time of enrollment
- Premature rupture of membranes in the current pregnancy at time of enrollment
- Known unrepaired maternal congenital heart disease requiring surgical correction
- Maternal heart failure
- Chronic kidney disease specifically requiring dialysis
- On greater than two antihypertensive medications at time of enrollment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: STAC-CAB Members
Staying Healthy After Childbirth - Community Advisory Board members (8-12 members) |
|
|
Aucune intervention: Lived Experience Group Members
Lived Experience Group members (8-12 members) |
|
|
Expérimental: PDSA Cycle Participants and CBO Staff
Black pregnant or postpartum persons and Community Based Organization Staff |
Conduct PDSA cycles and follow-up interviews and surveys for patients (3-5 per cycle, 10 total) and CBO staff (no less than 2) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Qualitative Summary of Barriers to Implementation of A-STAC
Délai: up to 4 weeks
|
Barriers to implementation of A-STAC in CBOs will be investigated via qualitative analysis of interviews and focus groups with STAC-CAB members. All feedback regarding barriers will be coded for themes summarized by participant count. |
up to 4 weeks
|
|
Qualitative Summary of Facilitators to Implementation of A-STAC
Délai: up to 4 weeks
|
Facilitators to implementation of A-STAC in CBOs will be investigated via qualitative analysis of interviews and focus groups with STAC-CAB members. All feedback regarding facilitators will be coded for themes summarized by participant count. |
up to 4 weeks
|
|
Qualitative Summary of Adaptations to STAC
Délai: up to 8 weeks
|
Adaptations to STAC will be analyzed from patient participant interviews and CBO staff participants post-PDSA cycles. Interviews will be coded for themes summarized by count. |
up to 8 weeks
|
|
The Acceptability of Intervention Measure (AIM)
Délai: up to 8 weeks
|
The Acceptability of Intervention Measure (AIM) measures intervention acceptability with 4 items ranked on a 5-point Likert-type scale from 1 = Completely Disagree to 5 = Completely Agree. Higher scores indicate higher acceptability. |
up to 8 weeks
|
|
The Intervention Appropriateness Measure (IAM)
Délai: up to 8 weeks
|
The Intervention Appropriateness Measure (IAM) measures intervention appropriateness with 4 items ranked on a 5-point Likert-type scale from 1 = Completely Disagree to 5 = Completely Agree. Higher scores indicate higher acceptability. |
up to 8 weeks
|
|
The Feasibility of Intervention Measure (FIM)
Délai: up to 8 weeks
|
The Feasibility of Intervention Measure (FIM) measures intervention feasibility with 4 items ranked on a 5-point Likert-type scale from 1 = Completely Disagree to 5 = Completely Agree. Higher scores indicate higher acceptability. |
up to 8 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Kara Hoppe, DO, PhD, University of Wisconsin, Madison
- Chercheur principal: Andrew Garbacz, PhD, University of Wisconsin, Madison
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2024-1594
- U48DP006793 (Subvention/contrat des NIH des États-Unis)
- Protocol Approved 5/14/26 (Autre identifiant: UW Madison)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .